“Swiss pharmaceutical company Roche is planning to move a new antibiotic into late stage clinical trials after early studies showed it had potential to tackle a common superbug that has become resistant to other treatments. 

If successful, it would be the first new class of antibiotic capable of killing acinetobacter or any other ‘Gram-negative’ bacteria to be developed for more than fifty years. This type of bug has a structure that makes it more difficult to treat.

Roche will launch a phase 3 trial for zosurabalpin at the end of the year, or early next year.”

From Financial Times.